News
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...
18d
Stocktwits on MSNAltimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A PositionAltimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...
Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.
After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and ...
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $12.00. Patrick Trucchio has given his Buy rating due to a ...
Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) Provided by GlobeNewswire May 19, 2025, 11:30:00 AM ...
Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.
Altimmune Inc. (NASDAQ: ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide.With a market ...
Altimmune Inc. (NASDAQ: ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide.With a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results